摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(4-(((3-(3-(trifluoromethoxy)phenyl)imidazo[1,2-b]pyridazin-6-yl)amino)methyl)piperidin-1-yl)ethanol | 1361951-12-3

中文名称
——
中文别名
——
英文名称
2-(4-(((3-(3-(trifluoromethoxy)phenyl)imidazo[1,2-b]pyridazin-6-yl)amino)methyl)piperidin-1-yl)ethanol
英文别名
2-[4-[[[3-[3-(Trifluoromethoxy)phenyl]imidazo[1,2-b]pyridazin-6-yl]amino]methyl]piperidin-1-yl]ethanol;2-[4-[[[3-[3-(trifluoromethoxy)phenyl]imidazo[1,2-b]pyridazin-6-yl]amino]methyl]piperidin-1-yl]ethanol
2-(4-(((3-(3-(trifluoromethoxy)phenyl)imidazo[1,2-b]pyridazin-6-yl)amino)methyl)piperidin-1-yl)ethanol化学式
CAS
1361951-12-3
化学式
C21H24F3N5O2
mdl
——
分子量
435.449
InChiKey
DQINITVVKFIKIO-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.6
  • 重原子数:
    31
  • 可旋转键数:
    7
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.43
  • 拓扑面积:
    74.9
  • 氢给体数:
    2
  • 氢受体数:
    9

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] HETEROCYCLIC PROTEIN KINASE INHIBITORS<br/>[FR] INHIBITEURS DE PROTÉINE KINASE HÉTÉROCYCLIQUES
    申请人:TOLERO PHARMACEUTICALS INC
    公开号:WO2013013188A1
    公开(公告)日:2013-01-24
    The present invention provides protein kinase having one of the following structures (I), (II) or (III): or a stereoisomer, prodrug, tautomer or pharmaceutically acceptable salt thereof, wherein R, R1, R2 and X are as defined herein. Compositions and methods for using the same in the treatment of cancer, autoimmune, inflammatory and other Pim kinase-associated conditions are also disclosed.
    本发明提供具有以下结构之一的蛋白激酶(I)、(II)或(III):或其立体异构体、前药、互变异构体或药用可接受盐,其中R、R1、R2和X如本文所定义。还公开了在治疗癌症、自身免疫、炎症和其他Pim激酶相关疾病中使用这些蛋白激酶的组合物和方法。
  • IMIDAZO[1,2-B]PYRIDAZINE AND PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS
    申请人:Xu Yong
    公开号:US20120058997A1
    公开(公告)日:2012-03-08
    The present invention provides protein kinase inhibitors comprising imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine compounds of the following structure (I) and (II): or a stereoisomer, prodrug or pharmaceutically acceptable salt thereof, wherein R, R 1 , R 2 and X are as defined herein. Compositions and methods for using the same in the treatment of cancer and other Pim kinase-associated conditions are also disclosed.
    本发明提供了蛋白激酶抑制剂,包括以下结构(I)和(II)的咪唑[1,2-b]吡啶吡唑[1,5-a]嘧啶化合物或其立体异构体、前药或药物可接受的盐,其中R、R1、R2和X如本文所定义。还公开了将其用于治疗癌症和其他Pim激酶相关疾病的组合物和方法。
  • HETEROCYCLIC PROTEIN KINASE INHIBITORS
    申请人:Xu Yong
    公开号:US20140329807A1
    公开(公告)日:2014-11-06
    The present invention provides protein kinase having one of the following structures (I), (II) or (III): or a stereoisomer, prodrug, tautomer or pharmaceutically acceptable salt thereof, wherein R, R 1 , R 2 and X are as defined herein. Compositions and methods for using the same in the treatment of cancer, autoimmune, inflammatory and other Pim kinase-associated conditions are also disclosed.
    本发明提供具有以下结构之一(I),(II)或(III)的蛋白激酶:或其立体异构体,前药,互变异构体或药学上可接受的盐,其中R,R1,R2和X如本文所定义。还公开了在治疗癌症,自身免疫,炎症和其他Pim激酶相关疾病中使用相同的组合物和方法。
  • Substituted imidazo[1,2-B]pyridazines as protein kinase inhibitors
    申请人:Tolero Pharmaceuticals, Inc.
    公开号:US10392392B2
    公开(公告)日:2019-08-27
    The present invention provides substituted imidazo[1,2-b]pyridazines that are useful as protein kinase inhibitors and have one of the following structures (I), (II) or (III): or a stereoisomer, prodrug, tautomer or pharmaceutically acceptable salt thereof, wherein R, R1, R2 and X are as defined herein. For example, a compound having the following structure: Compositions and methods for using the same in the treatment of cancer, autoimmune, inflammatory and other Pim kinase-associated conditions are also disclosed.
    本发明提供了可用作蛋白激酶抑制剂的取代咪唑并[1,2-b]哒嗪,它们具有以下结构之一 (I)、(II) 或 (III): 或其立体异构体、原药、同系物或药学上可接受的盐,其中 R、R1、R2 和 X 如本文所定义。例如,具有以下结构的化合物: 此外,还公开了用于治疗癌症、自身免疫性疾病、炎症和其他与 Pim 激酶相关的疾病的组合物和方法。
  • SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS
    申请人:Tolero Pharmaceuticals, Inc.
    公开号:US20170002014A1
    公开(公告)日:2017-01-05
    The present invention provides protein kinase having one of the following structures (I), (II) or (III): or a stereoisomer, prodrug, tautomer or pharmaceutically acceptable salt thereof, wherein R, R 1 , R 2 and X are as defined herein. Compositions and methods for using the same in the treatment of cancer, autoimmune, inflammatory and other Pim kinase-associated conditions are also disclosed.
查看更多